SYNGR2 serves as a prognostic biomarker and correlates with immune infiltrates in esophageal squamous cell carcinoma

Abstract

Background: Synaptogyrin-2 (SYNGR2) plays an important role in regulating membrane traffic in non-neuronal cells. However, the role of SYNGR2 in esophageal squamous cell carcinoma (ESCC) remains unclear.Methods: All original data were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases and integrated via R 3.5.3. SYNGR2 expression was explored in the TCGA and GEO databases. The correlations between SYNGR2 and cancer immune characteristics were analyzed via the TIMER and TISIDB databases.Results: In general, SYNGR2 was predominantly overexpressed and had reference values in the diagnosis and prognostic estimation of ESCC. Upregulated SYNGR2 was associated with poorer overall survival, disease-specific survival and T stage in ESCC. Mechanistically, we identified hub genes that included a total of 38 SYNGR2-related genes, which were tightly associated with the protein polyubiquitination pathway in ESCC patients. SYNGR2 expression was negatively related to the infiltrating levels of T helper cells. SYNGR2 methylation was positively correlated with the expression of chemokines (CCL2 and CXCL12), chemokine receptors (CCR1 and CCR2), immunoinhibitors (CXCL12 and TNFRSF4) and immunostimulators (CSF1R and PDCD1LG2) in ESCC.Conclusion: SYNGR2 may be used as a biomarker for determining prognosis and immune infiltration in ESCC.

Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma

“…Previous studies have found that the expression of SYNGR2 in esophageal cancer is related to immune cell infiltration [ 7 ]. Based on this, the Estimating Relative Subsets of RNA Transcripts (CIBERSORT) algorithm was used to determine the composition of 22 immune cell subsets based on gene expression profiles.…”

“…To date, the evidence of SYNGR2’s implications in cancer is very preliminary and lacks experimental validation. Li et al [ 7 ] reported the elevated expression of SYNGR2 in ESCC. High SYNGR2 expression was associated with poorer OS in ESCC.…”

“…Accordingly, SYNGR3 may be used as the basis for the diagnosis of renal cell carcinoma in the future [ 6 ]. With the continuous progress of research, Bin Li et al [ 7 ] found that SYNGR2 was associated with poorer overall survival, poorer disease-specific survival and T stage in ESCC. SYNGR2 may be used as a biomarker for determining prognosis and immune infiltration in ESCC.…”